No

Antihemophilic Agent

Short-term use (2-8 days) in hemophilia patients during and following tooth extraction to reduce or prevent hemorrhage, has also been used as an alternative to aminocaproic acid for subarachnoid hemorrhage

B

Acquired defective color vision, active intravascular clotting

Dosage modification required in patients with renal impairment; ophthalmic exam before and during therapy required if patient is treated beyond several days; caution in patients with cardiovascular, renal, or cerebrovascular disease; when used for subarachnoid hemorrhage, ischemic complications may occur

>10%: Gastrointestinal: Nausea, diarrhea, vomiting

1% to 10%:

Cardiovascular: Hypotension, thrombosis

Ocular: Blurred vision

<1%: Unusual menstrual discomfort

Chlorpromazine (may increase cerebral vasospasm and ischemia)

Incompatible with solutions containing penicillin

Forms a reversible complex that displaces plasminogen from fibrin resulting in inhibition of fibrinolysis; it also inhibits the proteolytic activity of plasmin

Half-life: 2-10 hours

Elimination: Primarily as unchanged drug (>90%) in urine

Children and Adults: I.V.: 10 mg/kg immediately before surgery, then 25 mg/kg/dose orally 3-4 times/day for 2-8 days

Oral: 25 mg/kg 3-4 times/day beginning 1 day prior to surgery

I.V.: 10 mg/kg 3-4 times/day in patients who are unable to take oral

Dosing adjustment/interval in renal impairment:

Cl_cr 50-80 mL/minute: Administer 50% of normal dose or 10 mg/kg twice daily I.V. or 15 mg/kg twice daily orally

Cl_cr 10-50 mL/minute: Administer 25% of normal dose or 10 mg/kg/day I.V. or 15 mg/kg/day orally

Cl_cr <10 mL/minute: Administer 10% of normal dose or 10 mg/kg/dose every 48 hours I.V. or 15 mg/kg/dose every 48 hours orally

May be given by direct I.V. injection at a maximum rate of 100 mg/minute; compatible with dextrose, saline, and electrolyte solutions

5-10 mg/mL is required to decrease fibrinolysis

None reported

None reported

No information available to require special precautions

No effects or complications reported

Report any signs of bleeding or myopathy, changes in vision; GI upset usually disappears when dose is reduced

Dosage modification required in patients with renal impairment

Injection: 100 mg/mL (10 mL)

Tablet: 500 mg

Astedt B, "Clinical Pharmacology of Tranexamic Acid," Scand J Gastroenterol Suppl, 1987, 137:22-5.

Royston D, "Blood-Sparing Drugs: Aprotinin, Tranexamic Acid, and Epsilon-Aminocaproic Acid," Int Anesthesiol Clin, 1995, 33(1):155-79.

Seto AH and Dunlap DS, "Tranexamic Acid in Oncology," Ann Pharmacother, 1996, 30(7-8):868-70.